CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

Hello, everyone, and welcome to ResMed's second-quarter ... reflecting the continuing demand for our AirSense 10 and AirSense 11 platforms. Device sales remained strong, growing double digits year ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

ResMed Inc.’s RMD adjusted earnings per share ... Global device sales were driven by strong market performance from both the AirSense 10 and the AirSense 11 platforms. A strong focus on ...

ResMed reported a revenue increase of 10% year-over-year ... attributed to manufacturing and cost improvements. The AirSense 11 has become the majority of ResMed's global product mix, which ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong ...